Somatostatin-dopamine chimeras: A novel approach to treatment of neuroendocrine tumors

Hormone and Metabolic Research

Volumn 43, Issue 12, 2011, Pages 854-857

  Culler, M D ^a  

^a IPSEN   (France)

Author keywords

5 BIM 23A760; Acromegaly; Adenomas; Cushings; Growth hormone; Heterodimer; Receptor

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BIM 23244; BIM 23A760; CORTICOTROPIN; DOPAMINE DERIVATIVE; DOPAMINE RECEPTOR; GROWTH HORMONE; HETERODIMER; INSULIN; OCTREOTIDE; PROLACTIN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

BINDING KINETICS; CANCER CELL; CANCER GROWTH; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GLYCEMIC CONTROL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DOPAMINE; HUMANS; NEUROENDOCRINE TUMORS; RECOMBINANT PROTEINS; SOMATOSTATIN;

PRIMATES;

EID: 82155172862     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1287769     Document Type: Review

References (32)

1. Shimon I, Taylor J E, Dong J Z, Bitonte R A, Kim S, Morgan B, Coy D H, Culler M D, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures: differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest: 1997; 99 789 798 (Pubitemid 27097683)
2. Shimon I, Yan X, Taylor J E, Weiss M H, Culler M D, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest: 1997; 100 2386 2396
3. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora A J, Grino M, Culler M D, Moreau J P, Enjalbert A, Ouafik L H. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab: 2000; 85 781 792 (Pubitemid 32273669)
4. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler M D, Moreau J P, Enjalbert A, Jaquet P. BIM-23244, A somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab: 2001; 86 140 145 (Pubitemid 32109787)
5. Zambre Y, Ling Z, Chen M C, Hou X, Woon C W, Culler M, Taylor J E, Coy D H, Van Schravendijk C, Schuit F, Pipeleers D G, Eizirik D L. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol: 1999; 57 1159 1164 (Pubitemid 29171692)
6. Culler M D. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis: 2004; 36 01 S17 S25 (Pubitemid 41115485)
7. Gouldson P R, Snell C R, Bywater R P, Higgs C, Reynolds C A. Domain swapping in G-protein coupled receptor dimers. Protein Eng: 1998; 11 1181 1193 (Pubitemid 29012128)
8. Hebert T E, Bouvier M. Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol: 1998; 76 1 11 (Pubitemid 29134992)
9. Jordan B A, Devin L A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature: 1999; 399 697 700 (Pubitemid 29289066)
10. Rocheville M, Lange D C, Kumar U, Sasi R, Patel R C, Patel Y C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem: 2000; 275 7862 7869 (Pubitemid 30159693)
11. Rocheville M, Lange D C, Kumar U, Patel S C, Patel R C, Patel Y C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science: 2000; 288 154 157 (Pubitemid 30203051)
12. Baragli A, Kumar U, Patel R C. Hetero-oligomerization of dopamine (D2R) and SST receptors (SSTR2) in CHO-K1 cells and cortical cultured neurons. Proceedings of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, USA: 2003; Abstract P2-669
13. Pfeiffer M, Koch T, Schrder H, Laugsch M, Hllt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem: 2002; 277 19762 19772 (Pubitemid 34967492)
14. Flogstad A K, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E, Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab: 1994; 79 461 465 (Pubitemid 24256536)
15. Li J K, Chow C C, Yeung V T, Mak T W, Ko G T, Swaminathan R, Chan J C, Cockram C S. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide. Aust N Z J Med: 2000; 30 457 461
16. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary: 1999; 1 115 120
17. Minniti G, Jaffrain-Rea M L, Baldelli R, Ferretti E, Caracciolo B, Bultrini A, Gulino A, Tamburrano G. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clin Ter: 1997; 148 601 607 (Pubitemid 127737510)
18. Culler M D, Taylor J E, Kim S, Woon C W, Datta R, Moreau J P. Chimeric analogs of somatostatin in pituitary adenoma. Somatostatin analogs: a state of the art review, a satellite symposium of the 5th European Congress of Endocrinology Turin, Italy: 2001
19. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor J E, Culler M D, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab: 2002; 87 5545 5552 (Pubitemid 36034358)
20. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau J P, Enjalbert A, Culler M D. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol: 2005; 153 135 141 (Pubitemid 41030524)
21. Culler M D, Dong J Z, Taylor J E, Touvay C, Teillot M, Marsais J, Fisch C, Moreau J-P. The somatostatin-dopamine chimeric molecule, BIM-23A760, is highly efficacious in suppressing GH in normal, cynomolgus monkeys (Macaca fascicularis). Proceedings of the 88th Annual Meeting of the Endocrine Society, Philadelphia, PA, USA: 2006; Abstract O9-6
22. Culler M D, Dong J Z, Taylor J E, Touvay C, Teillot M, Marsais J, Fisch C, Moreau J-P. The somatostatin-dopamine chimeric molecule, BIM-23A760, does not induce the insulin/glycemic effects observed with individual somatostatin or dopamine agonists in cynomolgus monkeys (Macaca fascicularis). 12th Meeting of the European Neuroendocrine Association, Athens, Greece: 2006
23. Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Albertelli M, Culler M D, Motta M, Minuto F, Magni P, Ferone D. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol: 2010; 207 309 317
24. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti A L, Culler M D, Barlier A, Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol: 2008; 158 595 603 (Pubitemid 351639596)
25. de Bruin C, Feelders R A, Lamberts S W, Hofland L J. Somatostatin and dopamine receptors as targets for medical treatment of Cushings Syndrome. Rev Endocr Metab Disord: 2009; 10 91 102
26. Hofland L, Feelders R, Theodoropoulou M, Stalla G, Cavagnini F, Giraldi F P, Culler M, Dong J, Taylor J, Barlier A, Jaquet P, Saveanu A. A multicenter in vitro study on the effects of the chimeric somatostatin/dopamine compound, BIM-23A760, on ACTH secretion by primary cultures of human corticotroph adenomas. 14th Congress of the European NeuroEndocrine Association, Liege, Belgium: 2010; Abstract OC-4.7
27. Florio T, Barbieri F, Spaziante R, Zona G, Hofland L J, van Koetsveld P M, Feelders R A, Stalla G K, Theodoropoulou M, Culler M D, Dong J, Taylor J E, Moreau J-P, Saveanu A, Gunz G, Dufour H, Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer: 2008; 15 583 596 (Pubitemid 351880845)
28. OToole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P, Barlier A. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol: 2006; 155 849 857 (Pubitemid 46040624)
29. Maiza J C, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M. Bennet Caron P. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol: 2007; 67 282 289 (Pubitemid 47076308)
30. Hochgeschwender U, Datta R, Dong J Z, Moreau J-P, Culler M D. The somatostatin-dopamine chimera, BIM-23A760, arrests pituitary adenoma growth in vivo. 90th Annual Meeting of the Endocrine Society, San Francisco: 2008; Abstract P3-758
31. Froehlich J, Ramis J, Lesage C, Obach R. Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) after Subcutaneous (s.c.) Administration (adm) of BIM23A760, a Chimeric Compound Combining Dopaminergic Agonist and Somatostatin Analogue, in Healthy Male Volunteers. 91st Annual Meeting of the Endocrine Society, Washington, DC: 2009; Abstract P3-685
32. Lesage C, Seymour C, Urbanavicius V, Beckers A, Kazanavicius G, Colao A. A Phase II Exploratory Study of BIM23A760 in Acromegalic Patients: Preliminary Results of Safety and Efficacy after a Single-Dose Administration. 91st Annual Meeting of the Endocrine Society, Washington, DC: 2009; Abstract P3-673